Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Blood glucose monitoring test systems for prescription point-of-care use: guidance for industry and Food and Drug Administration staff
Blood glucose monitoring test systems for prescription point-of-care use: guidance for industry and Food and Drug Administration staff
United States. Department of Health and Human Services, issuing body. United States. Food and Drug Administration, issuing body. Center for Devices and Radiological Health (U.S.), issuing body.
Publication:
[Silver Spring, MD] : Center for Devices and Radiological Health, September 29, 2020
This guidance document describes studies and information that FDA recommends be used when submitting premarket notifications (510(k)s) for blood glucose monitoring systems (BGMSs) which are for prescription point-of-care use. This guidance document is intended to guide manufacturers in conducting appropriate performance studies and preparing 510(k) submissions for these device types, and replaces the final guidance entitled “Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use” issued on October 11, 2016. This guidance is not meant to address self-monitoring blood glucose test systems (SMBGs) for over-the-counter (OTC) home use by lay-users. FDA addresses those device types in another guidance entitled “Self-Monitoring Blood Glucose Test Systems for Over-theCounter Use” (SMBG guidance). FDA is also issuing a revised SMBG guidance to reflect similar clarifications to the ones discussed in this guidance.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)